The effect of thalidomide and 2 analogs on collagen induced arthritis

Journal of Rheumatology

Volumn 25, Issue 5, 1998, Pages 964-969

  Oliver, Stephen J ^a   Cheng, Tammy P ^a   Banquerigo, Mona Lisa ^a   Brahn, Ernest ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis inhibition; Animal model; Collagen induced arthritis; Thalidomide; Tumor necrosis factor ; Vascular endothelial growth factor

Indexed keywords

2 (2,6 DIOXO 3 PIPERIDINYL)PHTHALIMIDINE; COLLAGEN; SUPIDIMIDE; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; DOSE RESPONSE; DRUG EFFECT; FEMALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION; RAT; TERATOGENICITY;

ANIMALS; ARTHRITIS, RHEUMATOID; COLLAGEN; DISEASE MODELS, ANIMAL; ENDOTHELIAL GROWTH FACTORS; FEMALE; IMMUNOSUPPRESSIVE AGENTS; LYMPHOKINES; RATS; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0031921590     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 1977;146:857-68.
2. Brahn E. Animal models of rheumatoid arthritis: clues to etiology and treatment. Clin Orthop Rel Res 1991;265:42-53.
3. Lenz W. A short history of thalidomide embryopathy. Teratology 1988;38:203-15.
4. Gutiérrez-Rodriguez O, Starusta-Bacal P, Gutiérrez-Montes O. Treatment of refractory rheumatoid arthritis - the thalidomide experience. J Rheumatol 1989;16:158-63.
5. Koch HP. Thalidomide and congeners as anti-inflammatory agents. Prog Med Chem 1985;22:166-242.
6. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of graft-versus-host disease. N Engl J Med 1992;326:1055-8.
7. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993;177:1675-80.
8. Sarno EN, Grau GE, Vieira LMM, Nery JA. Serum levels of tumor necrosis factor-α and interleukin-1β during leprosy reactional states. Clin Exp Immunol 1991;84:103-8.
9. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5.
10. Gordon GB, Spielberg SP, Blake DA, Balasubramanian V. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc Natl Acad Sci USA 1981;78:2545-8.
11. Connolly DT. Vascular permeability factor: a unique regulator of blood vessel function. J Cell Biochem 1991;47:219-23.
12. Ferrara N, Houck KA, Jakeman LB, Winer J, Leung DW. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991;47:211-8.
13. Kondo S, Asano M, Matsuo K, Ohmori I, Suzuki H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta 1994;1221:211-4.
14. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.
15. Fava RA, Olsen NJ, Spencer-Green G, et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994;180:341-6.
16. Koch AE, Harlow LA, Haines GK, et al. Vascular endothelial growth factor, a cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994;152:4149-56.
17. Peacock DJ, Banquerigo ML, Brahn E. Angiogenesis inhibition suppresses collagen arthritis. J Exp Med 1992;175:1135-7.
18. Brahn E, Peacock DJ, Banquerigo ML, Liu DL. Effects of tumor necrosis factor alpha (TNF-α) on collagen arthritis. Lymphokine Cytokine Res 1992;11:253-6.
19. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Therap 1965;6:303-6.
20. Günzler V. Thalidomide in human immunodeficiency virus patients. Drug Safety 1992;7:116-34.
21. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated monocytes. J Exp Med 1991;173:699-703.
22. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced-arthritis. Proc Natl Acad Sci USA 1992;89:9784-8.
23. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
24. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235:442-7.
25. Peacock DJ, Banquerigo ML, Brahn E. A novel angiogenesis inhibitor suppresses rat adjuvant arthritis. Cell Immunol 1995;160:178-87.
26. Sheskin J. Study with nine thalidomide derivatives in the lepra reaction. Int Soc Trop Dermatol 1978;17:82-4.
27. Shumacher HJ, Terapane J, Jordan RL, Wilson JG. The teratogenic activity of a thalidomide analog EM12 in rabbits, rats, and monkeys. Teratology 1972;5:233-40.
28. Cahen RL. Evaluation of the teratogenicity of drugs. Clin Pharmacol Therap 1964;5:480-514.
29. Goihman-Yahr M, Requena MA, Vallecalle-Suegart E, Convit J. Autoimmune diseases and thalidomide: II. adjuvant disease, experimental allergic encephalomyelitis, experimental allergic neuritis, of the rat. Int J Lepr 1974;42:266-75.
30. Crain E, McIntosh KR, Gordon G, Pestronk A, Drachman DB. The effect of thalidomide on experimental autoimmune myasthenia gravis. J Autoimmunity 1989;2:197-202.
31. Descotes J, Tedone R, Evreux JC. Enhancement of antibody response and delayed-type hypersensitivity by thalidomide in mice. Fundam Clin Pharmacol 1988;2:493-7.
32. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990;33:305-15.
33. Oliver SJ, Cheng TP, Banquerigo ML, Brahn E. Suppression of collagen induced arthritis with an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor. Cell Immunol 1995;166:196-206.